All In Biotech

Drug Trial Radar · NCT06647407

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

A Parallel-group Prevention, Phase II, Partially Blinded, Multi-stage Study to Investigate the Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine Formulations Compared With Licensed Meningococcal Vaccines When Administered Alone in Healthy Children (2 to 9 Years of Age) or Concomitantly With Routine Pediatric Vaccines in Toddlers (12 to 15 Months of Age) and Infants (2 Months of Age).

Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Nov 5, 2024

Primary completion

May 17, 2027

Study completion May 17, 2027

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Oct 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 56 days, up to 9 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age. The aim of the study is to assess 2 formulations of the MenPenta vaccine compared to licensed meningococcal vaccines when administered alone in children (Stage 1) or concomitantly with routine pediatric vaccines in toddlers (Stage 2) and infants (Stage 3). Study details include: The study duration per participant will be up to 12 months for children in Stage 1 and toddlers in Stage 2 and 16 to-19 months for infants in Stage 3.

Conditions

  • Meningococcal Immunization
  • Healthy Volunteers

Interventions

  • Pentavalent Meningococcal ABCYW vaccineBiological

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)

  • MenACYW conjugate vaccineBiological

    Pharmaceutical form: Solution for injection in vial Route of administration: Intramuscular (IM)

  • MenACYW conjugate vaccineBiological

    Pharmaceutical form: Powder and solvent for injectable solution in a pre-filled syringe Route of administration: Intramuscular (IM)

  • Meningococcal group B vaccineBiological

    Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)

  • ParacetamolDrug

    Pharmaceutical form:Suspension-Route of administration:oral

  • DTap-HepB-IPV-Hib vaccineBiological

    Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)

  • DTap-HepB-IPV-Hib vaccineBiological

    Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)

  • DTap-HepB-IPV-Hib vaccineBiological

    Pharmaceutical form: Oral solution in tube Route of administration: oral

  • Rotavirus vaccineBiological

    Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)

  • Pneumococcal 13-valent conjugate vaccineBiological

    Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with unsolicited immediate adverse events (AEs)Time frame: Within 30 minutes after each vaccination
  2. Number of participants with solicited injection site reactions or systemic reactionsTime frame: Within 7 days after each vaccination
  3. Number of participants with unsolicited AEsTime frame: Within 30 days after each vaccination
  4. Number of participants with serious adverse events (SAEs)Time frame: Throughout the study, from first visit until 180 days after the last vaccination
  5. hSBA meningococcal serogroups A, C, W, and Y antibody titers pre-dose and 30 days after the second and third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
  6. hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse pre-dose and 1 month after the second and third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
  7. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the second and third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
  8. Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each of serogroups A, C, W, and Y pre-dose and 1 month after the second and third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
  9. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 pre-dose and 1 month after second dose of vaccination against serogroup B, before and 30 days after third dose in infantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
  10. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 pre-dose and 1 month after the second dose of vaccination against serogroup B, before and 30 days after third dose in infantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
  11. hSBA meningococcal serogroup B seroresponse pre-dose and 1 month after the second dose of vaccination against serogroup B, before and 30 days after third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
  12. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) pre-dose and 1 month after the second dose of vaccination against serogroup B, before and 30 days after third dose in infant participantsTime frame: Day 01, Day 91, Day 181 and Day 211 (for Stage 3)
  13. Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all of serogroup B (ref. MenB strains) predose and 1 month after 2nd dose against serogroup B, before and 30 days after 3rd dose in infantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
  14. Percentage of participants with hSBA titers less than LLOQ against all serogroup B (ref. MenB strains) pre-dose and 1 month after the 2nd dose of vaccination against serogroup B, before and 30 days after 3rd dose in infantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
  15. hSBA meningococcal serogroups A, C, W, and Y antibody titers in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
  16. hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
  17. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the second dose children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
  18. Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each of serogroups A, C, W, and Y children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
  19. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
  20. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
  21. hSBA meningococcal serogroup B (reference MenB strains) vaccine seroresponse in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
  22. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
  23. Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all of serogroup B (reference MenB strains) in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
  24. Percentage of participants with hSBA titers less than the lower limit of quantification (LLOQ) against all serogroup B (reference MenB strains) in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211

Locations

39 sites in 9 countries. Site status is shown where the registry gives one.

  • Hospital das Clínicas da Universidade Federal de Minas Gerais- Site Number : 0760001

    Belo Horizonte, Minas Gerais, Brazil

  • Private Practice - Dr. Nelson Rosário- Site Number : 0760004

    Curitiba, Paraná, Brazil

  • Investigational Site Number : 2030003

    Jindřichův Hradec, Czechia

  • Investigational Site Number : 2030004

    Ostrava, Czechia

  • Investigational Site Number : 2030007

    Pilsen, Czechia

  • Investigational Site Number : 2030008

    Prague, Czechia

  • Investigational Site Number : 2030009

    Prague, Czechia

  • Investigational Site Number : 2080002

    Hvidovre, Denmark

  • Investigational Site Number : 2080003

    Odense, Denmark

  • Investigational Site Number : 2460006

    Espoo, Finland

  • Investigational Site Number : 2460001

    Helsinki, Finland

  • Investigational Site Number : 2460008

    Helsinki, Finland

  • Investigational Site Number : 2460005

    Jarvenpaa, Finland

  • Investigational Site Number : 2460004

    Oulu, Finland

  • Investigational Site Number : 2460002

    Seinäjoki, Finland

  • Investigational Site Number : 2460007

    Tampere, Finland

  • Investigational Site Number : 2760008

    Herxheim, Germany

  • Investigational Site Number : 2760006

    Hürth, Germany

  • Investigational Site Number : 2760007

    Hürth, Germany

  • Investigational Site Number : 2760005

    Krefeld, Germany

  • Investigational Site Number : 2760009

    Mönchengladbach, Germany

  • Investigational Site Number : 2760004

    Schönau am Königssee, Germany

  • Investigational Site Number : 2760003

    Wolfsburg, Germany

  • Investigational Site Number : 3400001

    San Pedro Sula, Honduras

  • Investigational Site Number : 3400002

    Tegucigalpa, Honduras

  • Investigational Site Number : 3400003

    Tegucigalpa, Honduras

  • Investigational Site Number : 6160006

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Investigational Site Number : 6160001

    Lodz, Lódzkie, Poland

  • Investigational Site Number : 6160005

    Trzebnica, Lower Silesian Voivodeship, Poland

  • Investigational Site Number : 6160003

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 6160002

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 6160004

    Siemianowice Śląskie, Silesian Voivodeship, Poland

  • Investigational Site Number : 7240009

    Madrid, Spain

  • Investigational Site Number : 7240004

    Madrid, Spain

  • Investigational Site Number : 7240007

    Seville, Sevilla, Spain

  • Investigational Site Number : 8260004

    Exeter, Devon, United Kingdom

  • Investigational Site Number : 8260007

    London, England, United Kingdom

  • Investigational Site Number : 8260009

    London, England, United Kingdom

  • Investigational Site Number : 8260010

    Southampton, Hampshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.